본문 바로가기
KERD
논문KCI 등재

알쯔하이머병과 소혈관성 치매에서 Donepezil 복용 후 K-MMSE의 변화와 의미 있는 K-MMSE 변화를 보이는 알쯔하이머병 환자의 특징

The change of K-MMSE following donepezil medication in patients with Alzheimer’s disease and small vessel dementia, and the characteristics of Alzheimer’s disease with meaningful K-MMSE change

김준|이유상|한일우|곽용태
대한생물정신의학회 (The Korean Society Of Biological Psychiatry)|2005.11|생물정신의학 (Journal of Korean Society of Biological Psychiatry)|제12권 제2호|pp. 17-28

2

조회

0

다운로드

2

인용

0

참고문헌

키워드

Donepezil·알쯔하이머병·소혈관성 치매· K-MMSE·반응군.Donepezil·Alzheimer’s disease·Small vessel dementia·K-MMSE·Responsive group.
주제분류정신과학

초록

Abstract

objectives：Donepezil is a widely used drug for the treatment of patients with Alzheimer’s disease(AD). The aim of the present study was to clarify the efficacy and the characteristics of responders to donepezil. Methods：Patients with probable AD(n=80；75.7 years) and small vessel dementia(SVD)(n=18；77.8 years) who received donepezil were retrospectively analyzed using Alzheimer’s registry, and three questions were asked：1) Does donepezil therapy improves cognitive symptoms in patients with dementia? 2) If donepezil improves cognitive symptoms, which items of the K-MMSE are improved? 3) What are the characteristics of responder to donepezil medication? Results：1) After donepezil medication, cognitive function measured by the K-MMSE was significantly improved in both types of dementia(AD and SVD), However, statistical differences were not found between these groups. 2) In a clinical trial of donepezil, the patients performed better than before mediation on KMMSE items assessing orientation, recall, construction, concentration, calculation. 3) In AD, the K-MMSE score before medication was closely related with response of donepezil. Conclusion：This study suggests that donepezil improves various cognitive functions in both types of dementia, and the responsive group had significantly lower K-MMSE scores than the non-responsive group before medication.

참고문헌 (32)

  1. "Alzheimer’s disease and senile dementia:loss ofneurons in the basal forebrain", 215, pp.1237~1239 (1982)
  2. "Selective loss of central cholinergicneurons in Alzheimer’s disease", 2, pp.1403~ (1976)
  3. "Cholinergic therapies for Alzheimer’s disease", 45, pp.425~431 (1995)
  4. "QSAR analysis of the substituted inanoneand benzylpiperidine rings of a series of indanonebenzylpiperidineinhibitors of acetylcholinesterase", 35, pp.584~589 (1992)
  5. "The efficacy and safety of donepezil in patients withAlzheimer’s disease results of a US multicenter", pp.293~303
  6. "DonepezilImproves Cognition and Global Function inAlzheimer Disease:A 15-Week,Double-blind,Placebo-Controlled Study", 158, pp.1021~1031 (1998)
  7. "A 24-week,double-blind,placebo-controlled trial ofdonepezil in patients with Alzheimer’s disease", 50, pp.136~145 (1998)
  8. "Cholinesterase Inhibitor Therapy StabilizesSymptoms of Alzheimer Disease", 14 (2000)
  9. "Use of cholinesterase inhibitors in clinicalpractice:evidence-based recommendations", 11, pp.131~145
  10. "Efficacy and tolerabilityof donepezil in vascular dementia positive results of a24-week", pp.2323~2332, multicenter
  11. "Donepezil in vascular dementia:arandomized,placebo-controlled study", 61, pp.479~486 (2003)
  12. "Theneurochemistry of vascular dementia", 5, pp.163~167 (1994)
  13. "Guidance for the clinical evaluation of antidementiadrugs" (1990)
  14. "A new rating scale forAlzheimer’s disease", 141, pp.1356~1364 (1984)
  15. "Validity and reliability of the Alzheimer’s DiseaseCooperative Study-Clinical Global Impression ofChange", 11(2), pp.~32 (1997)
  16. "Clinical diagnosis of Alzheimer’sdisease:report of the NINCDS-ADRDA Work Groupunder Auspices of Department of Health and HumanServices Task Force on Alzheimer’s disease", 34, pp.939~44 (1984)
  17. "Research criteria for subcorticalvascular dementia in clinical trials", 59, pp.23~30 (2000)
  18. "A new clinical scale for the staging of dementia", 140, pp.566~572 (1982)
  19. "A validity study on the KoreanMini-Mental State Examination", pp.300~308
  20. "National Institute for Clinical Excellence Guidance onthe Use of Donepezil and Galantaminefor the treatment of Alzheimer’s Disease" (2001)
  21. "Repeatedexposure to the Mini-Mental State Examinationand the Information-Memory-Concentration Test resultsin a practice effect in Alzheimer’s disease", 43, pp.1559~1563 (1993)
  22. "The consortium to establish a registry forAlzheimer’s disease Rates of cognitivechange in the longitudinal assessment of probableAlzheimer's disease", pp.2457~2465
  23. "Variability in annual Mini-Mental State Examination score in patients with probableAlzheimer disease:a clinical perspective of datafrom the Consortium to Establish a Registry for Alzheimer’sDisease", 56, pp.857~862 (1999)
  24. "a practical method for grading the cognitivestate of patients for the clinician"
  25. "Neuropathologic substrates of ischemicvascular dementia", 60, pp.658~659 (2000)
  26. "Efficacy and safety of memantine in patientswith mild to moderate vascular dementia", pp.~300
  27. "Response of patients with Alzheimer diseaseto rivastigmine treatment is predicted by the rate ofdisease progression", 58, pp.417~422 (2001)
  28. "Defining meaningfulchange in Alzheimer’s disease trials:the donepezil experience", 12, pp.39~48 (1999)
  29. "Apolipoprotein E4 allele as a predictorof cholinergic deficits and treatment outcome in Alzheimer’sdisease", 92, pp.12260~12264 (1995)
  30. "Presence or absenceof at least one E4 allele and gender are not predictive forthe response to donepezil treatment in Alzheimer’s disease", 12, pp.415~420 (2002)
  31. "Serum levels of tacrine in relationto clinical response in Alzheimer’s disease", 7, pp.115~119 (1992)
  32. "Clinical efficacy and safety of donepezilon cognitive and global function in patients withAlzheimer’s disease placebo-controlled study in Japan", 11, pp.299~313 (2000), multicenter

관련 논문AI추천

알츠하이머 치매 환자에서 치료 전 중증도에 따른 약물의 장기 치료 효과권인선, 김정란, 박유리, 서희원대한생물치료정신의학회 · 생물치료정신의학2021 · 제27권 제1호알츠하이머병에서 아세틸콜린에스테라제 억제제에 대한 치료 반응과 관련된 요인김정란, 이미지, 한송이대한생물치료정신의학회 · 생물치료정신의학2015 · 제21권 제2호알츠하이머병과 혈관성치매에서의 진행 정도에 따른 임상 양상의 차이김수영, 김응규, 김재우, 김태유, 박경원, 성상민, 손태홍, 안경숙, 유봉구, 윤성민, 윤수진, 이상찬, 정해관, 최문성, 홍태용대한신경과학회 · 대한신경과학회지2006 · 제24권 제4호순수 알츠하이머병 치매 환자군과 혼합성 치매 환자군에서 12개월간의 도네페질(Donepezil) 투여에 따른 치료 성적의 비교 평가강효신, 김도관, 김혜란, 문유진, 안인숙, 윤지혜, 이영민, 정재원, 황태영대한노인정신의학회 · 노인정신의학2010 · 제14권 제1호알쯔하이머병 환자의 인지기능 변화 및 예후인자: 1년 추적곽강호, 김상윤, 김태유, 성상민, 윤성민, 이은아, 인연권, 홍태용대한신경과학회 · 대한신경과학회지2005 · 제23권 제1호알츠하이머병 치매 환자에서 도네페질(Donepezil)에 대한 최초 투약군과 전환군 간의 임상적 효용 비교 평가： 12개월 추적관찰 연구강효신, 김도관, 김혜란, 문유진, 안인숙, 윤지혜, 이영민, 정재원, 황태영대한노인정신의학회 · 노인정신의학2010 · 제14권 제2호

이 간행물의 다른 논문 (16건)

뇌졸중 후 우울증의 진단과 치료신희영, 김재민pp. 3-16정신분열병환자에서 Taq I A 도파민 D2 수용체 다형성과 항정신병약물의 치료반응과의 연관강철중pp. 29-35정신분열병 환자에서의 혈중 Homocysteine 농도와 MTHFR C677T, A1298C의 유전자 다형성이영식, 전창무, 채석래, 나철pp. 36-45정신분열병과 양극성장애에서 뇌파 동시성의 비교분석김용규, 홍경수, 박종원, 이용석, 이유상, 신재공, 오홍석, 곽용태pp. 46-58흰쥐 C6 신경교종 세포에서 venlafaxine 그리고 dexamethasone 처리가 열충격 단백질 70의 발현에 미치는 영향노성원, 김석현, 이준석, 최미란, 양병환, 최인근, 채영규, 유재학, 오동렬pp. 59-69
원문 보기